EUVIMEDEUVIMED entdecken
Open Access

Engineered Escherichia coli for the in situ secretion of therapeutic nanobodies in the gut

Jason P Lynch, Coral González-Prieto, Analise Z Reeves, Sena Bae, Urmila Powale, Neha P Godbole, Jacqueline M Tremblay, Florian I Schmidt, Hidde L Ploegh, Vikram Kansra, Jonathan N Glickman, John M Leong und 3 weitere

Cell Host & Microbe · 2023-04 · 31 (4) · 634-649.e8

DOI: 10.1016/j.chom.2023.03.007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Host & Microbe, 2023-04. Verfasst von Jason P Lynch und 14 weiteren Autor:innen. Beteiligte Einrichtung: Center for Bacterial Pathogenesis, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA 02115, USA; De…. Hauptthemen laut MEDLINE: Single-Domain Antibodies, Colitis. Die Arbeit wurde bisher 119-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIDDK NIH HHS, Australian Government Department of Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Drug platforms that enable the directed delivery of therapeutics to sites of diseases to maximize efficacy and limit off-target effects are needed. Here, we report the development of PROT3EcT, a suite of commensal Escherichia coli engineered to secrete proteins directly into their surroundings. These bacteria consist of three modular components: a modified bacterial protein secretion system, the associated regulatable transcriptional activator, and a secreted therapeutic payload. PROT3EcT secrete functional single-domain antibodies, nanobodies (Nbs), and stably colonize and maintain an active secretion system within the intestines of mice. Furthermore, a single prophylactic dose of a variant of PROT3EcT that secretes a tumor necrosis factor-alpha (TNF-α)-neutralizing Nb is sufficient to ablate pro-inflammatory TNF levels and prevent the development of injury and inflammation in a chemically induced model of colitis. This work lays the foundation for developing PROT3EcT as a platform for the treatment of gastrointestinal-based diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Single-Domain AntibodiesColitisAnimalsMiceEscherichia coliTumor Necrosis Factor-alpha

Stichwörter der Autor:innen

TNFcolitisdesigner probioticengineered E. coliin situ drug deliveryinflammatory bowel diseaselive biotherapeuticnanobodytype III secretion

Substanzen

Single-Domain AntibodiesTumor Necrosis Factor-alpha

Autor:innen und Institutionen

  • Center for Bacterial Pathogenesis, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA 02115, USA; Department of Microbiology, Blavatnik Institute, Harvard Medical School,…
  • Departments of Immunology and Infectious Diseases and Harvard T.H. Chan Center for the Microbiome in Public Health, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.
  • Department of Infectious Disease and Global Health, Tufts Cummings School of Veterinary Medicine, North Grafton, MA 01536, USA.
  • Institute of Innate Immunity, Medical Faculty, University of Bonn, 53127 Bonn, Germany.
  • Boston Children's Hospital and Harvard Medical School, Boston, MA 02115, USA.
  • Vicero Inc., Shrewsbury, MA 01545, USA.

Förderung

  • NIAID NIH HHS
  • NIDDK NIH HHS
  • Australian Government Department of Education
  • NIH
  • Massachusetts General Hospital
  • Kenneth Rainin foundation
  • Crohn's and Colitis Foundation
  • IFM Therapeutics

Zitieren

APA

Lynch, J. P., González-Prieto, C., Reeves, A. Z., Bae, S., Powale, U., Godbole, N. P., Tremblay, J. M., Schmidt, F. I., Ploegh, H. L., Kansra, V., Glickman, J. N., Leong, J. M., Shoemaker, C. B., Garrett, W. S., & Lesser, C. F. (2023). Engineered Escherichia coli for the in situ secretion of therapeutic nanobodies in the gut. Cell Host & Microbe, 31(4), 634-649.e8. https://doi.org/10.1016/j.chom.2023.03.007

Vancouver

Lynch JP, González-Prieto C, Reeves AZ, Bae S, Powale U, Godbole NP, et al. Engineered Escherichia coli for the in situ secretion of therapeutic nanobodies in the gut. Cell Host & Microbe. 2023;31(4):634-649.e8. doi:10.1016/j.chom.2023.03.007

BibTeX
@article{Lynch2023,
  author = {Lynch, Jason P and González-Prieto, Coral and Reeves, Analise Z and Bae, Sena and Powale, Urmila and Godbole, Neha P and Tremblay, Jacqueline M and Schmidt, Florian I and Ploegh, Hidde L and Kansra, Vikram and Glickman, Jonathan N and Leong, John M and Shoemaker, Charles B and Garrett, Wendy S and Lesser, Cammie F},
  title = {Engineered Escherichia coli for the in situ secretion of therapeutic nanobodies in the gut},
  journal = {Cell Host & Microbe},
  year = {2023},
  volume = {31},
  number = {4},
  pages = {634--649.e8},
  doi = {10.1016/j.chom.2023.03.007}
}
Kostenlos starten →